We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MTD:NYSEMettler-Toledo International, Inc. Analysis

Data as of 2026-06-18 - not real-time

$1,144.84

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Mettler‑Toledo (MTD) is trading at $1,144.84, just above its 20‑day SMA of $1,143.92 but well below the 50‑day ($1,195.84) and 200‑day ($1,315.30) averages, indicating a bearish price trend. The RSI sits near the neutral 48 level and the MACD shows a bullish signal despite a negative line, while volume is decreasing and 30‑day volatility is high at 58.5%, suggesting short‑term price pressure. Fundamentally, the company delivered a 7.2% revenue growth, strong gross margin of 59% and operating margin of 23%, and beat Q1 earnings, prompting analysts to upgrade to a “buy” consensus. However, the DCF‑derived fair value of $437.16 is far below the current price, yielding an upside/downside metric of –15.9% and flagging the stock as significantly overvalued. Analyst coverage is positive, with a median target of $1,320, implying roughly 15% upside from current levels.
The lack of dividend payments and a negative book‑value per share (-$2.07) further limit income‑focused investors, while the company’s global exposure—especially noted geopolitical uncertainty in Europe—adds medium‑level geographic and regulatory risk. Overall, the stock’s strong cash generation and margin profile support a medium‑term buy case, but the current valuation gap and technical weakness counsel caution in the short term.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below 50‑day and 200‑day moving averages
  • Decreasing volume and high short‑term volatility
  • Current price far exceeds DCF fair value

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Q1 earnings beat and raised EPS guidance
  • Strong revenue growth and high operating margins
  • Analyst consensus “buy” with median target ~15% above price

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Sustained cash generation but negative book value
  • Overvaluation relative to intrinsic fair value
  • Exposure to global macro‑economic and regulatory environments

Key Metrics & Analysis

Financial Health

Revenue Growth7.20%
Profit Margin21.40%
P/E Ratio26.9
ROA20.57%
P/B Ratio-552.3
Op. Cash Flow$901.1M
Free Cash Flow$615.0M
Industry P/E24.1

Technical Analysis

TrendBearish
RSI48.3
Support$1,056.83
Resistance$1,198.02
MA 20$1,143.92
MA 50$1,195.84
MA 200$1,315.30
MACDBullish
VolumeDecreasing
Fear & Greed Index92.14

Valuation

Fair Value$437.16
Target Price$1,327.83
Upside/Downside15.98%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.99
Volatility58.53%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.